Compare BROS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BROS | ABVX |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 9.2B |
| IPO Year | 2021 | N/A |
| Metric | BROS | ABVX |
|---|---|---|
| Price | $51.19 | $124.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 11 |
| Target Price | $77.22 | ★ $130.09 |
| AVG Volume (30 Days) | ★ 5.6M | 984.0K |
| Earning Date | 02-12-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.73 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $1,537,335,000.00 | $6,231,374.00 |
| Revenue This Year | $28.88 | $6.80 |
| Revenue Next Year | $25.68 | N/A |
| P/E Ratio | $105.78 | ★ N/A |
| Revenue Growth | ★ 28.93 | N/A |
| 52 Week Low | $47.16 | $4.77 |
| 52 Week High | $86.88 | $148.83 |
| Indicator | BROS | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 34.46 | 57.47 |
| Support Level | $51.77 | $115.93 |
| Resistance Level | $57.50 | $116.72 |
| Average True Range (ATR) | 2.93 | 5.06 |
| MACD | -0.40 | 1.15 |
| Stochastic Oscillator | 9.58 | 95.24 |
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.